In vitro and in vivo studies on exogenous polyamines and α-difluoromethylornithine to enhance bone formation and suppress osteoclast differentiation [PDF]
Amino AcidsExogenous polyamines, including putrescine (PUT), spermidine (SPD), and spermine (SPM), and the irreversible inhibitor of the rate-limiting enzyme ornithine decarboxylase (ODC) of polyamine biosynthesis, α-difluoromethylornithine (DFMO), are implicated ...
Chien-Ching Lee +6 more
doaj +3 more sources
Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas. [PDF]
CNS Oncol, 2018 This review covers the literature between 1989 and 2007 on studies relevant to the neuro-oncology usage of eflornithine (α-difluoromethylornithine), an oral agent that irreversibly inhibits the enzyme ornithine decarboxylase.
Levin VA, Ictech SE, Hess KR.
europepmc +2 more sources
Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection [PDF]
VirusesDespite numerous research efforts and several effective vaccines and therapies developed against coronavirus disease 2019 (COVID-19), drug repurposing remains an attractive alternative approach for treatment of SARS-CoV-2 variants and other viral ...
Natalia A. Ignatenko +6 more
doaj +2 more sources
Dysregulation of the urea cycle – potential targets for treatment and diagnosis in prostate cancer [PDF]
Expert Reviews in Molecular MedicineBackground Prostate cancer (PCa) exhibits profound metabolic reprogramming, including dysregulation of the urea cycle (UC), an emerging driver of tumour growth, therapy resistance, and immune modulation.
Michael Ladurner +3 more
doaj +2 more sources
Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells [PDF]
Amino AcidsOncogenic mutations in the K-RAS small GTPase occur in more than 90% of human PDACs and cause dysregulation of multiple metabolic pathways, including polyamine metabolism.
Hwudaurw Chen +4 more
doaj +2 more sources
Repurposing With Purpose: Treatment of Bachmann-Bupp Syndrome With Eflornithine and Implications for Other Polyaminopathies. [PDF]
Am J Med Genet C Semin Med GenetABSTRACT Rare diseases impact approximately 1 in 10 people worldwide, and yet, less than 5% of all rare diseases currently have an approved treatment option available. This is due to many challenges unique to rare diseases, including small, diverse patient populations, the cost of drug development that is not proportionate to the number of patients who
Bupp CP +7 more
europepmc +2 more sources
Combined inhibition of polyamine biosynthesis and uptake blocks Candida albicans virulence [PDF]
mBioPolyamines, small organic polycations, are essential for life, and cells maintain polyamines via synthesis and uptake. Recently, we identified Hol1 as the high-affinity polyamine transporter in Saccharomyces cerevisiae.
Arya Vindu +6 more
doaj +2 more sources
Evidence against putrescine and polyamines as endogenous mediators of fever
, 1985 Endogenous concentrations of putrescine, spermidine, spermine and related biosynthetic enzymes were not affected by the administration of bacterial endotoxin and the subsequent development of fever in rabbits.
Haegele, K. D., Dascombe, M. J.
core +9 more sources
Medical Sciences, 2023 Recent identification of four additional polyaminopathies, including Bachmann–Bupp syndrome, have benefited from previous research on Snyder–Robinson syndrome in order to advance from research to treatment more quickly.
Julianne Michael +13 more
doaj +1 more source
Frontiers in Oncology, 2021 Personized treatment of breast cancer is still a challenge, and more treatment options for breast cancer are warranted. Combination therapies have been a highly appreciated strategy for breast cancer treatment in recent years, and the development of new ...
Hongyan Ma +15 more
doaj +1 more source